These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36553542)

  • 21. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.
    Rafehi S; Ramos Valdes Y; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
    Endocr Relat Cancer; 2016 Mar; 23(3):147-59. PubMed ID: 26647384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanical activation and expression of HSP27 in epithelial ovarian cancer.
    Buckley M; Kramer M; Johnson B; Huskin G; Berry J; Sewell-Loftin MK
    Sci Rep; 2024 Feb; 14(1):2856. PubMed ID: 38310132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell adhesion molecule profiles, proliferation activity and p53 expression in advanced epithelial ovarian cancer induced malignant ascites-Correlation of tissue microarray and cytology microarray.
    Toth L; Nagy B; Mehes G; Laszlo E; Molnar PP; Poka R; Hernadi Z
    Pathol Res Pract; 2018 Jul; 214(7):978-985. PubMed ID: 29801775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis.
    Yu Y; Lyu C; Li X; Yang L; Wang J; Li H; Xin Z; Xu X; Ren C; Yang G
    Cancer Lett; 2024 Aug; 596():217022. PubMed ID: 38849014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.
    Cai Q; Zhao Z; Antalis C; Yan L; Del Priore G; Hamed AH; Stehman FB; Schilder JM; Xu Y
    FASEB J; 2012 Aug; 26(8):3306-20. PubMed ID: 22767227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer.
    Singel KL; Grzankowski KS; Khan ANMNH; Grimm MJ; D'Auria AC; Morrell K; Eng KH; Hylander B; Mayor PC; Emmons TR; Lénárt N; Fekete R; Környei Z; Muthukrishnan U; Gilthorpe JD; Urban CF; Itagaki K; Hauser CJ; Leifer C; Moysich KB; Odunsi K; Dénes Á; Segal BH
    Br J Cancer; 2019 Jan; 120(2):207-217. PubMed ID: 30518816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
    Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
    Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
    Front Immunol; 2022; 13():956224. PubMed ID: 36032075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exosomes from Human Omental Adipose-Derived Mesenchymal Stem Cells Secreted into Ascites Promote Peritoneal Metastasis of Epithelial Ovarian Cancer.
    Qu Q; Liu L; Cui Y; Chen Y; Wang Y; Wang Y
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment.
    Mao TL; Fan MH; Dlamini N; Liu CL
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
    Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
    Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
    Song M; Yeku OO; Rafiq S; Purdon T; Dong X; Zhu L; Zhang T; Wang H; Yu Z; Mai J; Shen H; Nixon B; Li M; Brentjens RJ; Ma X
    Nat Commun; 2020 Dec; 11(1):6298. PubMed ID: 33293516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.
    Truxova I; Cibula D; Spisek R; Fucikova J
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization.
    Chen X; Ying X; Wang X; Wu X; Zhu Q; Wang X
    Oncol Rep; 2017 Jul; 38(1):522-528. PubMed ID: 28586039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenomic Profiling of Epithelial Ovarian Cancer Stem-Cell Differentiation Reveals GPD1 Associated Immune Suppressive Microenvironment and Poor Prognosis.
    Chen LY; Huang RL; Su PH; Chu LH; Weng YC; Wang HC; Lai HC; Wen KC
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
    Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating Tumor Evolution via Genomic Profiling of Individual Tumor Spheroids in a Malignant Ascites.
    Kim S; Kim S; Kim J; Kim B; Kim SI; Kim MA; Kwon S; Song YS
    Sci Rep; 2018 Aug; 8(1):12724. PubMed ID: 30143682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of lnc-MyD88 and its relationship with the prognosis of patients with epithelial ovarian cancer].
    Zhu Y; Huang JM; Zhang GN; Li JM; Huang J
    Zhonghua Fu Chan Ke Za Zhi; 2022 Feb; 57(2):117-124. PubMed ID: 35184472
    [No Abstract]   [Full Text] [Related]  

  • 40. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.